Neuland Laboratories (524558) Q2 24/25 earnings summary

Executive summary

• Q2 FY25 total income was INR 315.2 crores, down from INR 422.8 crores in Q2 FY24, reflecting business volatility and a particularly weak quarter compared to previous periods.

• Management expects FY25 to be flat versus FY24, with growth momentum anticipated to return in FY26, supported by a strong order pipeline and new facility launches.

• Strategic focus remains on sustainable long-term growth, customer acquisition, capacity expansion, and process optimization.

• Unaudited financial results for the quarter and half year ended September 30, 2024, were approved by the Board on November 6, 2024.

• The business is characterized by lumpy, uneven performance due to the nature of the CDMO and specialty GDS segments.

Financial highlights

• Q2 FY25 EBITDA was INR 65.7 crores (20.8% margin), down from Q2 FY24, with gross margin at 56.3% versus 59.8% a year ago.

• Profit after tax for Q2 FY25 was INR 32 crores, compared to INR 89.1 crores in Q2 FY24; EPS for the quarter was INR 24.9.

• H1 FY25 revenue was INR 759.6 crores, a 3.3% decline year-over-year; H1 EBITDA was INR 194.3 crores, down from INR 239.6 crores in H1 FY24.

• Free cash flow generated in H1 FY25 was INR 45.8 crores, partly used for term loan repayment and capex investment of INR 103.5 crores.

• Q1 FY25 and H1 FY25 included an exceptional profit of INR 20.6 crores from transfer of investment property.

Outlook and guidance

• FY25 is expected to close flat compared to FY24, a revision from earlier moderate growth expectations, due to order timing and execution delays.

• High growth is anticipated from FY26 onward, driven by new facility completion and commercial launches in the CMS segment.

• Management remains cautiously optimistic, citing a strong order pipeline and favorable medium- to long-term industry trends.

• No explicit forward-looking guidance provided in the statutory results, but a significant legal dispute regarding land allotment was resolved.